Estee Lauder Companies Inc (EL): what the price assumes

In the published model solve dated 2026-Q2, anchored at $103.39, Estee Lauder Companies Inc (EL) is priced for today's economics sustained for ~5.9 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/EL

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 10.1% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.8%); the inversion above states its own rate.

Per-Model Detail (n=12)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 11.9%); the trailing year was depressed.

Bullet Takeaways

• Skin Care is 49% of the business, Makeup 29% and Fragrance 17%, and the reset is showing up unevenly: in the nine months to March 31, 2026 operating cash flow reached $1.2 billion against $0.7 billion a year earlier, while reported operating margin in the March quarter still fell to 6.7% from 8.6%.
• The price is the demanding part, at about 32 times company-wide operating profit, near the top of the peer group, and it needs operating margin to roughly reach 12% against the 7.5% the company earns on a trailing basis.
• Management's own preliminary FY2027 view is organic net sales growth of 3% to 5% with adjusted operating margin approaching 13%, which is the number to test against the reported line as restructuring charges roll off.

Bull Case

Run this company through a standard screen and it looks broken. Book value per share is under eleven dollars, the trailing bottom line is negative, and the reported operating margin sits at 7.5%. Every one of those figures is true. None of them describes the business. What they describe is a company two years into dismantling and rebuilding its cost base, where the charges for doing so land in the reported line while the benefits arrive later and elsewhere. In the March 2026 quarter, reported operating income fell 19% to $249 million; on the company's own adjusted basis, which strips the restructuring charges and an $84 million litigation contingency, operating margin expanded 360 basis points to 15.0% from 11.4%. Both numbers are real. They are measuring different things.

The gross margin is the tell, because it is the hardest line to manufacture. It reached 76.4% in the March quarter against 75.0% a year earlier. That is the highest in this cohort by a distance: ELF runs 70.7%, OLPX 70.0%, IPAR 64.0%, COTY 63.2%, CL 60.1% and KVUE 58.4%. Seventy-six cents of gross profit on the dollar is what prestige brand equity looks like in accounting terms. Consumers pay for the name on the jar, and no amount of restructuring noise below the gross line changes that fact.

Cash conversion turned before earnings did, which is usually the honest early signal in a turnaround. Operating cash flow for the nine months to March 31, 2026 was $1,197 million against $671 million in the prior-year period, and free cash flow reached $891 million against $276 million, helped by capital expenditure falling to $306 million from $395 million. Net earnings for those nine months came to $298 million against a loss of $587 million a year earlier, a swing that owes much to the absence of the $861 million of goodwill and intangible impairment recorded in the prior period.

Geography is doing something the headlines have not caught up with. Reported operating income in Asia/Pacific rose 13% in the March quarter and 33% over the nine months, and management described high single-digit organic growth in Mainland China with share gains against prestige beauty overall. China has been the source of nearly every negative surprise this company has delivered in recent memory. A region that turns from the largest drag to a growth contributor changes the arithmetic of the whole recovery, because it is where the fixed cost of the brand portfolio was always meant to be leveraged.

Fragrance is the second lever, and it is the category where the economics are best and the competition is most fragmented. Organic fragrance sales grew double digits over the first nine months of fiscal 2026. IPAR, which operates the licensed side of the same category, runs an 18.0% operating margin on $1.49 billion of revenue, which is a useful marker for what a well-run fragrance business earns. Estée Lauder owns its brands rather than licensing them, so the ceiling on that economics is higher, not lower. The question was never whether the assets were good. It was whether the cost structure sitting on top of them could be fixed.

Bear Case

ELF grew revenue 24.6% over the trailing year on a 70.7% gross margin, and its own filing states the strategy without embarrassment: "Delivering premium quality products at extraordinary prices is at the heart of our value proposition", backed by marketing and digital spending of $318.8 million, roughly 24% of net sales. That is a competitor spending a quarter of its revenue talking directly to the customer, at price points that make a department store counter look like an anachronism. COTY is coming at the same customer from the other side, describing its push into "body mists and masstige fragrances", which is precisely the category where Estée Lauder's growth is currently strongest. The threat is not that either company beats Estée Lauder on prestige. It is that the definition of what counts as prestige is being renegotiated by people who did not build their businesses around a beauty hall.

The category itself has been punishing operators of scale. Skin Care is the single largest piece of Estée Lauder, at 49% of the business. It is also the category where CL recorded "a non-cash charge of $794 aftertax ($919 pretax) to adjust the carrying values of goodwill and intangible assets related to the skin health business", where KVUE's revenue was essentially flat over the trailing year, and where COTY shrank 3.6% and ran a negative operating margin. The larger, more diversified competitors are writing down what they paid for the thing that constitutes half of this company.

Now put that against what the price requires. At roughly 32 times company-wide operating profit, the multiple sits at the very top of the peer distribution, well past the upper quartile. What that price embeds is growth pinned at the fastest rate the business could self-fund, sustained for about seven years, plus an operating margin that has to roughly reach 12% against the 7.5% the company earns today. Closing four and a half points of profitability and then holding them is a decade-long project, not a quarter's work. Of the companies that reached that kind of pace, roughly three in ten held it for that long.

The basis question matters more here than in most reports. Management's preliminary fiscal 2027 view is an adjusted operating margin approaching 13%, which sounds like the requirement is already in hand. But adjusted excludes restructuring charges, and restructuring charges have been a recurring feature rather than a one-time event: they rose by $127 million year over year in the March quarter alone. A company that adjusts out the same category of cost every year is not really adjusting; it is reclassifying. The price is asking for the reported number, and on that basis the March quarter came in at 6.7% against 8.6% a year earlier.

Finally, the balance sheet leaves less room than the cash balance suggests. Total borrowings stood at $7,312 million at March 31, 2026 against cash of $3,126 million, and cash interest paid over the nine months was $229 million. Operating profit covers interest roughly 3.3 times over. That is workable, not comfortable, for a business whose reported earnings have been negative on a trailing basis and whose recovery depends on spending more, not less, on the consumer-facing investment that drives it.

Valuation

The most useful way to read this price is as a bet on duration rather than on rate. At about 32 times company-wide operating profit, what today's price embeds is not an unusual growth rate for a single year. It is growth pinned at the fastest pace the business could fund out of its own cash flow, held for roughly seven years. The rate is inside what Estée Lauder has recently delivered. The persistence is the demanding part, and the record on persistence is thin: only about 29% of comparable fast-growers sustained that pace for that long.

The second way to state the same bet is in margin terms, which is more concrete. Operating margin has to roughly reach 12% and stay there. The trailing figure is 7.5%. That is the entire investment case compressed into two numbers, and the gap between them is what a buyer at this price is underwriting. It is worth being exact about which basis those figures sit on. Both are reported margins, including restructuring charges. Management's guidance is framed on an adjusted basis that excludes them, and on that basis the company already expects to approach 13% in fiscal 2027. The two figures are not in conflict; they are simply not the same measurement, and the price is asking for the harder one.

The methods split more starkly here than in most reports. Only the revenue-multiple lens reaches this price, landing within a percent of it. Everything built on profit or on the balance sheet lands far below: the price sits roughly 7.4 times where the earnings-power methods put it and about 7.8 times the book-value methods, and around 1.5 times the cash-flow projections. That pattern is not a verdict that the shares are eight times too expensive. It is a mechanical consequence of what a depressed profit base does to any method that capitalizes profit. The honest reading is narrower and more useful: at today's price, sales are the only fundamental that supports the valuation, and every method that requires the profit to actually show up first does not.

Against the cohort, the position is unusual. On 14.8 billion dollars of revenue, Estée Lauder is the second largest name in this group behind CL at 20.8 billion dollars, and it earns the highest gross margin of any of them at 76.4% in the most recent quarter. Yet its trailing operating margin of 7.5% sits below IPAR's 18.0%, KVUE's 17.2% and CL's 15.4% on far smaller cost bases. The distance between the best gross margin in the group and a bottom-quartile operating margin is, precisely, the operating cost structure the restructuring program exists to address.

On the balance sheet, the filed figures are what matter. Borrowings totalled $7,312 million at March 31, 2026 against $3,126 million of cash, with equity of $3,993 million. Operating profit covers interest about 3.3 times. The share count has been essentially flat, growing about 0.1% a year over four years, so nothing here is being funded by dilution. What the leverage does is remove the option of being patient: a company with this much borrowing against a trailing operating margin in the mid single digits needs the margin recovery to be on schedule, not eventually.

Catalysts

The March 2026 quarter, reported May 1, 2026, was the one where the guidance moved up. Net sales rose 5% to $3,712 million with organic sales up 2%, gross margin expanded to 76.4% from 75.0%, and the company raised its full-year fiscal 2026 outlook, now expecting organic sales growth at the high end of its prior range and adjusted operating margin expansion approaching 300 basis points. Reported diluted earnings per share were $0.24 against $0.44 a year earlier, the difference sitting almost entirely in restructuring charges and an $84 million loss contingency related to a potential securities class action settlement.

The forward markers management gave are specific enough to track. The preliminary fiscal 2027 view is organic net sales growth of 3% to 5% and adjusted operating margin approaching 13%, described alongside full deployment of the company's One Operating Ecosystem. Fiscal 2026 is framed as the year sales growth returns and adjusted operating margin expands for the first time since fiscal 2022. Both claims are testable against the next two reported quarters.

Two items sit outside the operating story. The securities class action contingency was recorded in the March quarter at $84 million net of estimated probable insurance recoveries, so a final settlement is a dated event still to come. And the effective tax rate jumped to 50.3% from 34.0% a year earlier, which the company attributed to recently enacted U.S. tax legislation. On an adjusted basis the rate was 31.8%, so the reported and adjusted lines will keep diverging on tax as well as on restructuring until the legislation's effect settles.

Peer Cohorts (Per Segment, With Filing Citations)

Skin Care (reported)

• COTY (COTY INC.)
• FY2025 10-K: …agile innovation, social media advocacy, and expansion into body mists and masstige fragrances. Skincare remains a strategic focus, but achieving scale takes time, and we will pursue this while remaining very mindful of the investment demand. We also continue to advance key sustainability priorities. Strategic…
• FY2025 10-K: …and behaviors, both on-line and in-store. We have introduced new ways to customize the consumer experience, including using AI-powered tools to provide personalized advice on selecting and using products, and augmented reality tools that invite customers to virtually try products with curated looks, tutorials and…
• ELF (e.l.f. Beauty, Inc.)
• FY2025 10-K: …the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations, and future growth prospects. PART I Item 1. Business. Overview e.l.f. Beauty, Inc.…
• FY2025 10-K: …sales, a change in the order pattern of one or more of our large retail customers could cause a significant fluctuation of our quarterly results or impact our liquidity. Trademarks and Other Intellectual Property We believe that our intellectual property has substantial value and has contributed significantly to the…
• IPAR (INTERPARFUMS, INC.)
• FY2025 10-K: Chief Customer, Marketing, and Digital Officer at Marks & Spencer PLC. There, he spearheaded the department store's digital transformation, positioning marksandspencer.com as one of the top three online destinations for clothing and footwear in the United Kingdom. He also led M&S's Beauty transformation initiative,…
• FY2025 10-K: …the finished products for us and then deliver them to one of our distribution centers. Product Liability Our United States based operations maintain product liability coverage in an amount of $ 10.0 million, and our European based operations maintain product liability coverage in an amount of €25 million…
• KVUE (Kenvue Inc.)
• FY2025 10-K: Care (Digestive Health, Smoking Cessation, Eye Care, and Other) Skin Health and Beauty Face and Body Care Hair, Sun, and Other Essential Health Oral Care Baby Care Other Essential Health (Women's Health, Wound Care, and Other) The Company's product categories as a percentage of Net sales for the fiscal twelve months…
• FY2025 10-K: …in the winter or, in the case of Benadryl ® and Zyrtec ® , during high allergy seasons in the spring and the fall. In addition, in our Skin Health and Beauty segment, sales of our products that contain SPF are typically higher in preparation for the summer, and sales of our products that contain moisturizers are…
• UL (UNILEVER PLC)
• FY2025 20-F: …90% of turnover. Deodorants grew low single-digit, with positive volume and price, led by strong growth in Dove. The continued success of whole-body deodorants fuelled growth, offset by a volume decline in Latin America amid softer market conditions. Across our other categories, Skin Cleansing grew mid-single digit,…
• FY2025 20-F: …good performance, with many achieving double-digit growth, supported by science-led, premium innovation and social-first marketing. Leandro Barreto Chief Marketing Officer - Unilever and Beauty & Wellbeing ABOUT BEAUTY & WELLBEING Our categories: Hair Care, Prestige Beauty, Skin Care and Wellbeing Our Power Brands:…
• CL (COLGATE-PALMOLIVE COMPANY)
• FY2025 10-K: …dishwashing liquids, Ajax, Fabuloso and Murphy household cleaners and Suavitel, Soupline, Fluffy and Cuddly fabric conditioners. Sales of Oral, Personal and Home Care products accounted for 44%, 17% and 16%, respectively, of our total worldwide Net sales in 2025. Geographically, Oral Care is a substantial part of our…
• FY2025 10-K: Comparability In the fourth quarter of 2025, we recorded a non-cash charge of $794 aftertax ($919 pretax) to adjust the carrying values of goodwill and intangible assets related to the skin health business. Given lower than expected category growth rates and weaker than expected performance, particularly in China, we…

Makeup (reported)

• COTY (COTY INC.)
• FY2025 10-K: …efforts, including in connection with new products in our skincare and prestige cosmetics portfolios ; • changes in the demand for our products due to declining or depressed global or regional economic conditions, and declines in consumer confidence or spending, whether related to the economy (such as austerity…
• FY2025 10-K: …agile innovation, social media advocacy, and expansion into body mists and masstige fragrances. Skincare remains a strategic focus, but achieving scale takes time, and we will pursue this while remaining very mindful of the investment demand. We also continue to advance key sustainability priorities. Strategic…
• ELF (e.l.f. Beauty, Inc.)
• FY2025 10-K: …affinity and loyalty. Total expenses for marketing and digital in the fiscal year ended March 31, 2025 were $318.8 million, approximately 24% of our net sales. • Productivity Model . Founded as a digitally native brand, our flagship e.l.f. Cosmetics brand is the only top five mass cosmetics brand with its own…
• FY2025 10-K: …to Every Eye, Lip and Face Delivering premium quality products at extraordinary prices is at the heart of our value proposition, democratizing access for millions of consumers who otherwise couldn't have the best of beauty. We believe that equally important is what goes into our products (and what doesn't) and how…
• IPAR (INTERPARFUMS, INC.)
• FY2025 10-K: June 30, 2031 David Beckham December 31, 2047 Donna Karan/DKNY December 31, 2032, plus a 5 -year optional term if certain sales targets are met Emanuel Ungaro December 31, 2031, plus a 5 -year optional term if certain sales targets are met Ferragamo December 31, 2031, plus a 5 -year optional term if certain sales…
• FY2025 10-K: …Brexit, they are subject to the United Kingdom regulation of The UK Schedule 34 to the Product Safety and Metrology Regulations 2019 . As of the date of this report, Interparfums products are in compliance with these regulations. Trademarks The market for our products depends to a significant extent upon the value…
• KVUE (Kenvue Inc.)
• FY2025 10-K: …realization of benefits associated with our supply chain optimization initiatives, and savings from Our Vue Forward resulting in administrative expense reductions. Skin Health and Beauty Segment Skin Health and Beauty Segment Net Sales The Skin Health and Beauty Segment Net sales were $4.1 billion and $4.2 billion…
• FY2025 10-K: …and distributors to ensure that products do not contain false or misleading labeling, are not adulterated, and are not manufactured under unsanitary conditions. Inspections also may arise from consumer or competitor complaints filed with the FDA. In the event that the FDA determines that one of our products fails to…
• UL (UNILEVER PLC)
• FY2025 20-F: …good performance, with many achieving double-digit growth, supported by science-led, premium innovation and social-first marketing. Leandro Barreto Chief Marketing Officer - Unilever and Beauty & Wellbeing ABOUT BEAUTY & WELLBEING Our categories: Hair Care, Prestige Beauty, Skin Care and Wellbeing Our Power Brands:…
• FY2025 20-F: …90% of turnover. Deodorants grew low single-digit, with positive volume and price, led by strong growth in Dove. The continued success of whole-body deodorants fuelled growth, offset by a volume decline in Latin America amid softer market conditions. Across our other categories, Skin Cleansing grew mid-single digit,…

Fragrance (reported)

• COTY (COTY INC.)
• FY2025 10-K: …our priorities to capitalize on structural tailwinds in the fragrance market. We are leveraging our leadership in fragrance innovation, licensing, and manufacturing to expand across price points, from mass to ultra-premium. With slower growth in China's beauty market, we have shifted focus to a broader set of…
• FY2025 10-K: …agile innovation, social media advocacy, and expansion into body mists and masstige fragrances. Skincare remains a strategic focus, but achieving scale takes time, and we will pursue this while remaining very mindful of the investment demand. We also continue to advance key sustainability priorities. Strategic…
• IPAR (INTERPARFUMS, INC.)
• FY2025 10-K: …cosmetics other than fragrances. Fragrance Portfolio Abercrombie & Fitch - In 2014 , we entered into a worldwide license to create, produce and distribute new fragrances and fragrance related products under the Abercrombie & Fitch brand name. We distribute these fragrances in specialty stores, department stores and…
• FY2025 10-K: Fierce distribution agreement is to drive, over time, more consistency between the products that are carried in the Abercrombie & Fitch stores and unaffiliated retailers. In 2025, we introduced a new fragrance duo, 100% Passion , and the Fierce Reserve extension. Anna Sui - In 2011 , we entered into an exclusive…
• UL (UNILEVER PLC)
• FY2025 20-F: …and South Africa. Home & Hygiene grew mid-single digit, led by Domestos and Cif, supported by premium innovations such as Infinite Clean. Fabric Enhancers grew high single-digit, led by volume, with Comfort benefiting from premium formats and fragrance-led innovations such as boosters. Operating profit decreased by…
• FY2025 20-F: …90% of turnover. Deodorants grew low single-digit, with positive volume and price, led by strong growth in Dove. The continued success of whole-body deodorants fuelled growth, offset by a volume decline in Latin America amid softer market conditions. Across our other categories, Skin Cleansing grew mid-single digit,…
• ELF (e.l.f. Beauty, Inc.)
• FY2025 10-K: …sales, a change in the order pattern of one or more of our large retail customers could cause a significant fluctuation of our quarterly results or impact our liquidity. Trademarks and Other Intellectual Property We believe that our intellectual property has substantial value and has contributed significantly to the…
• FY2025 10-K: …to Every Eye, Lip and Face Delivering premium quality products at extraordinary prices is at the heart of our value proposition, democratizing access for millions of consumers who otherwise couldn't have the best of beauty. We believe that equally important is what goes into our products (and what doesn't) and how…

Hair Care (reported)

• OLPX (OLAPLEX HOLDINGS, INC.)
• FY2025 10-K: …haircare market, OLAPLEX operates in the fastest growing category of premium haircare (which we refer to herein as "prestige haircare"), which Euromonitor forecasts will grow at a compound annual growth rate of approximately 7% globally from 2024 to 2029, as consumers "trade up" and increase their haircare spending…
• FY2025 10-K: …new product introductions or promotional and planning activities undertaken by us or our customers, which may impact the timing of purchases or order placement. Competition There is significant competition within each market where our products are sold. Competition in the beauty industry is based on a variety of…
• KVUE (Kenvue Inc.)
• FY2025 10-K: Care (Digestive Health, Smoking Cessation, Eye Care, and Other) Skin Health and Beauty Face and Body Care Hair, Sun, and Other Essential Health Oral Care Baby Care Other Essential Health (Women's Health, Wound Care, and Other) The Company's product categories as a percentage of Net sales for the fiscal twelve months…
• FY2025 10-K: …following three reportable business segments: • Self Care. Our Self Care product categories include: Cough, Cold, and Allergy; Pain Care; and Other Self Care (Digestive Health, Smoking Cessation, Eye Care, and Other). Major brands in the segment include Benadryl ® , Calpol ® , Motrin ® , Nicorette ® , Rhinocort ® ,…
• UL (UNILEVER PLC)
• FY2025 20-F: …good performance, with many achieving double-digit growth, supported by science-led, premium innovation and social-first marketing. Leandro Barreto Chief Marketing Officer - Unilever and Beauty & Wellbeing ABOUT BEAUTY & WELLBEING Our categories: Hair Care, Prestige Beauty, Skin Care and Wellbeing Our Power Brands:…
• FY2025 20-F: …positive price offsetting volume declines. Dove delivered double-digit growth driven by the successful launch of its renovated hair care range. Meanwhile, Sunsilk and Clear were impacted by softness in several emerging markets and deliberate tail brand portfolio rationalisation. Core Skin Care grew mid-single digit,…
• CL (COLGATE-PALMOLIVE COMPANY)
• FY2025 10-K: …dishwashing liquids, Ajax, Fabuloso and Murphy household cleaners and Suavitel, Soupline, Fluffy and Cuddly fabric conditioners. Sales of Oral, Personal and Home Care products accounted for 44%, 17% and 16%, respectively, of our total worldwide Net sales in 2025. Geographically, Oral Care is a substantial part of our…
• FY2025 10-K: Comparability In the fourth quarter of 2025, we recorded a non-cash charge of $794 aftertax ($919 pretax) to adjust the carrying values of goodwill and intangible assets related to the skin health business. Given lower than expected category growth rates and weaker than expected performance, particularly in China, we…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.